How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rachel Wharton Rachel Wharton is a writer covering kitchen appliances. She ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

AT last we have the pleasure of welcoming the largest work so far written by one who is perhaps the greatest living master of experimental morphology. It has received admirable treatment by the Yale ...

The Overnight Express Autoinduction Systems enable regulated protein expression in Escherichia coli without the need to monitor the culture or add inducer during cell growth and are marketed ...